Study study type PathologyT1T0Patientssample sizesROB Results

la/mBC - HR-positive - 1st line (L1) breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 1st line (L1)

versus exemestane plus ridaforolimus
dalotuzumab plus ridaforolimus plus exemestane
MK-8669-064, 2017
  NCT01605396
RCTla/mBC - HR-positive - 1st line (L1)dalotuzumab plus ridaforolimus plus exemestaneridaforolimus plus exemestanePatients with metastatic or locally advanced ER-positive and HER2-negative BC40 / 40some concern
inconclusive
  • inconclusive 18 % increase in progression or deaths (PFS) (PE)